Clostridium difficile ribotypes in Austria: a multicenter, hospital-based survey

Wiener Klinische Wochenschrift

Volumn 127, Issue 15-16, 2015, Pages 587-593

  Indra, Alexander ^a   Schmid, Daniela ^a   Huhulescu, Steliana ^a   Simons, Erica ^a   Hell, Markus ^b   Stickler, Karl ^c   Allerberger, Franz ^a  

^a AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Mortality; Moxifloxacin; Nosocomial; Resistance; Ribotype

Indexed keywords

CLINDAMYCIN; METRONIDAZOLE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRIA; BACTERIUM ISOLATE; CHILD; FECES ANALYSIS; HEALTH SURVEY; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; RIBOTYPING; AGE DISTRIBUTION; CLASSIFICATION; CLINICAL TRIAL; CROSS INFECTION; EPIDEMIOLOGY; FEMALE; GENETICS; HEALTH CARE SURVEY; HOSPITALIZATION; INCIDENCE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PSEUDOMEMBRANOUS COLITIS; RISK FACTOR; SEX RATIO; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUSTRIA; CHILD; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HEALTH CARE SURVEYS; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RIBOTYPING; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE; YOUNG ADULT;

EID: 84939269399     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-015-0808-5     Document Type: Article

References (34)

1. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377:63–73.
2. Allerberger F. Time to act against Clostridium difficile infection. Clin Microbiol Infect. 2012;18(S6):1.
3. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–84.
4. Health Protection Agency. Voluntary surveillance of Clostridium difficile, England, Wales and Northern Ireland: 2013. Infection report 8 (Number 7) Published electronically on: 21 February 2014. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/339374/Clostridium_difficile_voluntary_surveillance_2013.pdf. Accessed: 25 May 2015.
5. Goorhuis A, Van der Kooi T, Vaessen N, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis. 2007;45:695–703.
6. Kuijper EJ, Barbut F, Brazier JS, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe. Euro Surveill. 2008;13:18942.
7. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis. 2008;47:1162–70.
8. Hensgens MP, Keessen EC, Squire MM, et al. Clostridium difficile infection in the community: a zoonotic disease? Clin Microbiol Infect. 2012;18:635–45.
9. Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald LC, Limbago BM. Clostridium difficile in retail meat products, USA 2007. Emerg Infect Dis. 2009;15:819–812.
10. Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis. 2011;24:370–6.
11. Indra A, Lassnig H, Baliko N, et al. Clostridium difficile: a new zoonotic agent? Wien Klin Wschr. 2009;121:91–5.
12. Gilca R, Frenette C, Theriault N, Fortin E, Villeneuve J. Attributing cause of death for patients with Clostridium difficile infection. Emerg Infect Dis. 2012;18:1707–8.
13. Hell M, Sickau K, Chmelizek G, et al. Absence of Clostridium difficile in asymptomatic hospital staff. AJIC. 2012;40:1023–4.
14. Indra A, Huhulescu S, Schneeweis M, et al. Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping. J Med Microbiol. 2008;57:1377–82.
15. Huhulescu S, Sagel U, Fiedler A, et al. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium Difficile. J Med Microbiol. 2011;60:1206–12.
16. Cohen SH1, Gerding DN, Johnson S, Kelly CP, et al. Society for healthcare epidemiology of America; infectious diseases society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.
17. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium Difficile. N Engl J Med. 2005;353:2433–41.
18. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–80.
19. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173:1037–42.
20. Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012;55:1661–8.
21. Indra A, Huhulescu S, Hasenberger P, et al. First isolation of Clostridium difficile PCR ribotype 027 in Austria. Euro Surveill. 2006;11(37):pii = 3046.
22. Indra A, Huhulescu S, Kernbichler S, et al. First cases of Clostridium difficile PCR ribotype 027 acquired in Austria. Euro Surveill. 2008;13(20):pii = 18875.
23. Indra A, Huhulescu S, Fiedler A, Kernbichler S, Blaschitz M, Allerberger F. Outbreak of Clostridium difficile 027 infection in Vienna, Austria 2008–2009. Euro Surveill. 2009;14(17):pii = 19186.
24. Centers for Disease Control and Prevention. Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012;61:157–62.
25. Rupnik M, Widmer A, Zimmermann O, Eckert C, Barbut F. Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J Clin Microbiol. 2008;46:2146.
26. Sirard S, Valiquette L, Fortier LC. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol. 2011;49:4040–6.
27. Barbut F, Rupnik M. 027, 078, and others: Going beyond the numbers (and away from the hypervirulence). Clin Infect Dis. 2012;55:1669–72.
28. Patel TA, Smith R, Hopkins S. Ribotyping in the detection of Clostridium difficile outbreaks in a single university hospital. J Hosp Infect. 2013;83:77–9.
29. He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium Difficile. Nat Genet. 2013;45:109–13.
30. Tenover FC, Tickler E, Persing D. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother. 2012;56:2929–32.
31. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile Infection. Clin Infect Dis. 2008;46 Suppl 1:S19–S31.
32. Wenisch JM, Equiluz-Bruck S, Fudel M, et al. Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use. Antimicrob Agents Chemother. 2014;58:5079–5083.
33. de With K, Allerberger F, Amann S, et al. S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. AWMF-Registernummer 092/001. 2013. http://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Antibiotika_Anwendung_im_Krankenhaus_2013-12.pdf. Accessed: 9 March 2015.
34. Davies KA, Longshaw CM, Davis GL, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2015;14:1208–19.